Balkanpharma, a recent acquisition by Pharmaco of Iceland, called upon Austin to design and manage the construction of a new Tablet Production Facility in Dupnitza, Bulgaria.

Summer 2003

The plant was designed to produce approximately 3 billion tablets per year for 20 to 30 generic formulations of plain or coated types with possible hard gelatine capsules at a later date. The

Austin Company designed the facility, specified the production process equipment and managed the procurement, costs and construction through to commissioning and validation.

Key Criteria

Facility to be in production as soon as possible
Flexible space with a capability for expansion
Efficient and pleasant working environment
Control costs within budget, minimise maintenance and energy costs
Full compliance with cGMP standards and MCA requirements

Results

First cGMP and MCA compliant ST&T design in Bulgaria
Facility completed within 12 months of start on site
Quality of unit is comparable to the best in UK
Costs were 7% lower than budget
Manufacturing capability available within 6 months of completing construction
Safety statistics better than a comparable project in the UK

The Director of Operations of Balkanpharma, Mr Jon Bergsson, claimed that: By using Austin as a single source we were able to overcome major obstacles in a proficient manner and have a validated facility available on time and within budget.

For more information call Austin on Tel: +44 (0) 1923 432 658
or Email: enquiries@austin.co.uk